Clinical applications of selected liquid biopsy biomarkers in pancreatic cancer with a focus on ctDNA CTCs and exosome derived biomarkers
Current evidence indicates that ctDNA is the most mature platform for molecular profiling, prognostic assessment, treatment monitoring, and MRD research, although sensitivity remains limited in localized disease.